Premium
Squamous cell carcinoma of the anal canal at The Queen Elizabeth Hospital: A local experience
Author(s) -
KICHENADASSE Ganessan,
ZAKARIA Jasiah,
RODDA David J,
HEWETT Peter J,
RIEGER Nicholas A,
STEPHENS Jacqueline H,
PITTMAN Ken,
PATTERSON Kevin,
BORG Martin,
PRICE Timothy J
Publication year - 2007
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/j.1743-7563.2007.00115.x
Subject(s) - medicine , chemoradiotherapy , anal canal , surgery , radiation therapy , sphincter , basal cell , colostomy , fluorouracil , anal carcinoma , carcinoma , chemotherapy , rectum
Aim: Concurrent chemoradiotherapy is the standard treatment for squamous cell carcinoma of anal canal. We describe our experience of treating such patients at our center. Methods: Patients with anal squamous cell carcinoma were treated with a uniform sphincter preserving protocol at The Queen Elizabeth Hospital, South Australia. Standard radiotherapy along with 5‐fluorouracil (750 mg/m 2 on days 1–5 and days 29–32) and mitomycin C (12 mg/m 2 on day 1 only) was given to eligible patients. Results: Of the 34 patients included in this study, nearly 60% were women. Most (89.3%) had T1‐2 disease. One‐third had nodal involvement. Twenty‐seven had chemoradiotherapy, six had local excision alone and one had radiotherapy alone. Among those who had chemoradiation, 71.5% had a complete response and remained colostomy free until the last follow‐up. Most completed the treatment without major side‐effects. The 3 and 5‐year disease free survival rate was 62% and 53%, respectively. All patients who failed chemoradiation underwent salvage surgery with a median survival time of 32.5 months. Conclusion: Sphincter preservation is the goal for anal cancers. Chemoradiotherapy is an important modality to achieve this goal.